Covid-19 vaccine roll-out expected in less than 3 months in UK: Report

A mass roll-out of a Covid-19 vaccine in Britain could be finished in as little as three months, the Times reported, citing government scientists

covid-19, vaccine, coronavirus
Reuters
2 min read Last Updated : Oct 03 2020 | 4:32 PM IST

(Reuters) - A mass roll-out of a COVID-19 vaccine in Britain could be finished in as little as three months, the Times reported, citing government scientists.

Scientists working on the Oxford vaccine hope regulators approve it before the beginning of 2021, the newspaper said.

A full COVID-19 immunization programme, which would exclude children, could be quicker than experts predicted, the Times said, adding that health officials estimate that every adult could receive a dose of the vaccine within six months.

The European Medicines Agency (EMA) said on Thursday it has started reviewing data on AstraZeneca and Oxford University's potential COVID-19 vaccine, in real time, the first of such moves aimed at speeding up any approval process in the region for a vaccine.

The news of the European review also raises chances of the British vaccine, which is seen as leading the race for a successful vaccine against COVID-19, becoming the first to be approved in Europe for the disease caused by the novel coronavirus which has killed more than a million people globally.

The Times report added that plans under consideration by government include allowing a much wider group of healthcare staff to administer the vaccine, setting up of drive-through vaccination centres and recruiting help of armed forces.

 

 

(Reporting by Sabahatjahan Contractor in Bengaluru; Additional reporting by Rebekah Mathew in Bengaluru; Editing by Diane Craft and Matthew Lewis)

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

Topics :CoronavirusCoronavirus VaccineUK

First Published: Oct 03 2020 | 4:30 PM IST

Next Story